Center of Excellence in Vaccine Research and Development,
Chulalongkorn University (Chula VRC)
Chula VRC was formally established in 2017 under the supervision of Professor Kiat Ruxrungtham. We consists of faculty staff and researchers with common interest in vaccine research and development to work together and share their knowledge and experience leading to the strength of the team. We focuses not only on vaccines against infectious diseases, such as HIV infection, dengue fever, leptospirosis, and emerging infections including novel corona virus disease (COVID-19) but also vaccines against non-infectious diseases including house dust mite allergy.
Key Contact Persons
Latest News & Events
From BioNet-Asia ChulaCov19 BNA159 is a COVID–19 mRNA vaccine developed by Chulalong
เปิดรับสมัครอาสาสมัครสุขภาพดีสำหรับโครงการ ChulaCov19 BNA159 mRNA vaccine คุณสมบัติ อายุ
A COVID-19 vaccine made by BioNet-Asia in Ayutthaya, Thailand, should be cheaper than the
Dr.Chanchai Sittipunt, Dr.Nakorn Premsri, Dr.Suthipong Watcharasin and Dr.Kiat Ruxrungtham greetings to three Prince Mahidol Award 2021 laureates
Amid a global shortage of vaccines and a new wave of COVID-19 infections, some countries in Southeast Asia are rushing to develop their own coronavirus shots.
COVID19 Vaccine Tracker – Chulalongkorn University: ChulaCov19
